OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Cancer is 77. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Enhancing childhood cancer targetability	720
Shooting for multiplexed pathology with Orion	558
PARP11 interfer(on)es with CAR T cell efficacy	516
A macrophage-activated abscopal effect	420
An oncolytic circular RNA therapy	385
Single-cell transcriptomic landscape deciphers olfactory neuroblastoma subtypes and intra-tumoral heterogeneity	337
Considering molecular alterations as pan-cancer tissue-agnostic targets	329
Author Correction: Breaking the performance ceiling for neoantigen immunogenicity prediction	314
Author Correction: Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	295
Author Correction: IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2− breast cancer via CX3CR1+ macrophages	289
Author Correction: RIOK1 phase separation restricts PTEN translation via stress granules activating tumor growth in hepatocellular carcinoma	255
Gut decisions in CAR T cell therapy	217
Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80	200
Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial	190
MALAT1 protects dormant tumor cells from immune elimination	186
Breaking frontiers with multidisciplinary cancer research	163
A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma	155
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial	152
The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC	150
ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung	139
A low-coverage liquid biopsy for lung cancer	138
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer	137
Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling	133
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms	131
Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study	127

The cGAS–STING pathway and cancer	125
Expanding the options for KRAS inhibition	124
Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor	123
Palmitate oxidation drives a pro-metastatic post-translational modification	123
A molecular glue halts RAS–MAPK signaling	118
The importance of being generous	117
Bone marrow progenitor-like cells against leukemia cure	116
Stress granules shape metabolic reprogramming and drug resistance	115
Shaping the microenvironment in peritoneal metastases	114
Impact of context-dependent autophagy states on tumor progression	109
Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity	109
crossNN is an explainable framework for cross-platform DNA methylation-based classification of tumors	109
Adoptively transferred tumor-specific IL-9-producing cytotoxic CD8+ T cells activate host CD4+ T cells to control tumors with antigen loss	109
A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma	108
Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial	107
Advancing therapeutics in small-cell lung cancer	107
Determinants of resistance and response to melanoma therapy	107
Innate immunity drives epithelial cell plasticity during prostate tumor formation	105
Sarcoma ecotypes determine immunotherapy benefit	105
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer	101
Antibody avidity meets multiple myeloma	101
Thriving in diverse ecosystems	100
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma	98
Evolving landscape of nasopharyngeal carcinoma therapy	97
Cancer-derived mitochondria fuel fibroblasts to become pro-tumorigenic	93
Inflammation meets translation in AML	92
Key insights from ESMO Congress 2025	92
SCRN1 confers hepatocellular carcinoma resistance to ferroptosis by stabilizing GPX4 via STK38-mediated phosphorylation	89
Sex-specific gut microbiota and neutrophil senescence in bladder cancer	89
A comeback for checkpoint inhibition in multiple myeloma	88
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling	87
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers	85
INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas	84
Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial	84
A tumor-derived metabolite primes the leptomeningeal pre-metastatic niche	83
Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes	83
Cycling back to folate metabolism in cancer	82
A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia	82
Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: the CONFIDENT-B single-center, non-randomized clinical trial	81
Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis	81
Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer	79
Regulatory T cells play a crucial part in radio-immunotherapy resistance of brain tumors	79
Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms	79
MCL1 inhibitor BRD-810 kills cancer cells while minimizing risk of cardiotoxicity	79
Radioligand cancer therapy comes to the fore	79
Immunotargeting of a recurrent AML-specific neoantigen	78
Multimodal data integration improves immunotherapy response prediction	78
First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer	78
Dual inhibition of EGFR and PI3K with a single drug	78
Building a translational cancer dependency map for The Cancer Genome Atlas	77

Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping	77
CHD1 status drives divergent metabolic pathways in SPOP-mutant prostate cancer	77